220 related articles for article (PubMed ID: 15934109)
1. Impact of managed care on the use of biologic agents for rheumatoid arthritis.
Yelin EH; Trupin LS; Katz PP
Arthritis Rheum; 2005 Jun; 53(3):423-30. PubMed ID: 15934109
[TBL] [Abstract][Full Text] [Related]
2. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings.
Ward MM; Lubeck D; Leigh JP
J Rheumatol; 1998 Apr; 25(4):641-9. PubMed ID: 9558163
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and impact of managed care for persons with rheumatoid arthritis in 1994 and 1999.
Yelin E; Trupin L; Katz P
Arthritis Rheum; 2002 Apr; 47(2):172-80. PubMed ID: 11954011
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices.
Yelin EH; Henke CJ; Kramer JS; Nevitt MC; Shearn M; Epstein WV
N Engl J Med; 1985 Apr; 312(15):962-7. PubMed ID: 3974686
[TBL] [Abstract][Full Text] [Related]
6. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
Criswell LA; Such CL; Yelin EH
J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
[TBL] [Abstract][Full Text] [Related]
7. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings.
Yelin EH; Criswell LA; Feigenbaum PG
JAMA; 1996 Oct; 276(13):1048-53. PubMed ID: 8847766
[TBL] [Abstract][Full Text] [Related]
8. A comparison of functional outcomes after hip fracture in group/staff HMOs and fee-for-service systems.
Coleman EA; Kramer AM; Kowalsky JC; Eckhoff D; Lin M; Hester EJ; Morgenstern N; Steiner JF
Eff Clin Pract; 2000; 3(5):229-39. PubMed ID: 11185328
[TBL] [Abstract][Full Text] [Related]
9. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
10. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
[TBL] [Abstract][Full Text] [Related]
11. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
12. Antirheumatic drug use and the risk of acute myocardial infarction.
Suissa S; Bernatsky S; Hudson M
Arthritis Rheum; 2006 Aug; 55(4):531-6. PubMed ID: 16874796
[TBL] [Abstract][Full Text] [Related]
13. The risk of hospitalized infection in patients with rheumatoid arthritis.
Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
J Rheumatol; 2008 Mar; 35(3):387-93. PubMed ID: 18260176
[TBL] [Abstract][Full Text] [Related]
14. The effect of Medicare health care systems on women with breast and cervical cancer.
Kirsner RS; Ma F; Fleming L; Trapido E; Duncan R; Federman DG; Wilkinson JD
Obstet Gynecol; 2005 Jun; 105(6):1381-8. PubMed ID: 15932833
[TBL] [Abstract][Full Text] [Related]
15. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
17. Inpatient utilization by dual Medicare-Medicaid eligibles in Medicare risk HMOs and fee for service, California, 1991-1996.
Sloss EM; Dhanani N; O'Leary JF; Lopez MS; Melnick G
Manag Care Interface; 2004 Dec; 17(12):30-4, 41. PubMed ID: 15656377
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
19. Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example.
Schwenkglenks M; Preiswerk G; Lehner R; Weber F; Szucs TD
J Epidemiol Community Health; 2006 Jan; 60(1):24-30. PubMed ID: 16361451
[TBL] [Abstract][Full Text] [Related]
20. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.
Lubeck DP
Pharmacoeconomics; 2001; 19(8):811-8. PubMed ID: 11596833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
